Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Helicobacter pylori | 10 | 2012 | 380 | 1.850 |
Why?
|
| Helicobacter Infections | 7 | 2011 | 390 | 1.400 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2020 | 157 | 1.100 |
Why?
|
| Hepatitis, Alcoholic | 2 | 2018 | 109 | 1.030 |
Why?
|
| Inflammatory Bowel Diseases | 10 | 2020 | 2429 | 0.670 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2020 | 145 | 0.630 |
Why?
|
| Hyperammonemia | 1 | 2020 | 80 | 0.620 |
Why?
|
| Gap Junctions | 1 | 2020 | 229 | 0.610 |
Why?
|
| Nucleotidyltransferases | 1 | 2020 | 242 | 0.590 |
Why?
|
| Gastrointestinal Agents | 4 | 2020 | 510 | 0.580 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2020 | 144 | 0.580 |
Why?
|
| Arteriovenous Malformations | 1 | 2020 | 397 | 0.540 |
Why?
|
| Drug Tolerance | 1 | 2018 | 363 | 0.520 |
Why?
|
| Liver Transplantation | 2 | 2018 | 2412 | 0.500 |
Why?
|
| Colitis, Ulcerative | 7 | 2020 | 1915 | 0.470 |
Why?
|
| Patient Care Management | 1 | 2017 | 303 | 0.460 |
Why?
|
| Crohn Disease | 4 | 2020 | 2283 | 0.430 |
Why?
|
| Dendritic Cells | 5 | 2012 | 2747 | 0.420 |
Why?
|
| Panniculitis, Peritoneal | 1 | 2012 | 11 | 0.400 |
Why?
|
| Liver Diseases | 1 | 2020 | 1303 | 0.370 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2012 | 169 | 0.350 |
Why?
|
| DNA, Bacterial | 3 | 2012 | 1477 | 0.340 |
Why?
|
| Hepatocytes | 4 | 2020 | 1247 | 0.340 |
Why?
|
| Biological Therapy | 2 | 2020 | 140 | 0.310 |
Why?
|
| Colitis | 3 | 2012 | 1239 | 0.300 |
Why?
|
| Liver | 3 | 2020 | 7562 | 0.300 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 1808 | 0.300 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2018 | 2329 | 0.290 |
Why?
|
| Bacterial Vaccines | 1 | 2010 | 400 | 0.290 |
Why?
|
| Alcoholism | 1 | 2018 | 1975 | 0.280 |
Why?
|
| Gastric Mucosa | 1 | 2009 | 602 | 0.270 |
Why?
|
| Patient Selection | 2 | 2020 | 4255 | 0.270 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 4348 | 0.260 |
Why?
|
| Immune Evasion | 1 | 2009 | 377 | 0.260 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2007 | 137 | 0.250 |
Why?
|
| Colectomy | 3 | 2019 | 697 | 0.240 |
Why?
|
| Liver Neoplasms | 2 | 2018 | 4353 | 0.230 |
Why?
|
| Salvage Therapy | 1 | 2011 | 1272 | 0.230 |
Why?
|
| Drug Eruptions | 1 | 2007 | 335 | 0.220 |
Why?
|
| Interleukin-17 | 1 | 2009 | 921 | 0.220 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2007 | 664 | 0.210 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 2 | 2017 | 265 | 0.200 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2009 | 1811 | 0.190 |
Why?
|
| Second-Look Surgery | 1 | 2019 | 27 | 0.160 |
Why?
|
| Recurrence | 3 | 2018 | 8501 | 0.160 |
Why?
|
| Ammonia | 1 | 2020 | 244 | 0.160 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 415 | 0.150 |
Why?
|
| Drug Hypersensitivity | 1 | 2007 | 902 | 0.150 |
Why?
|
| Anti-Retroviral Agents | 1 | 2007 | 1787 | 0.140 |
Why?
|
| Interleukin-10 | 3 | 2012 | 1183 | 0.140 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 607 | 0.140 |
Why?
|
| Cytokines | 2 | 2012 | 7421 | 0.140 |
Why?
|
| Opportunistic Infections | 1 | 2020 | 376 | 0.140 |
Why?
|
| Histocytochemistry | 1 | 2018 | 696 | 0.140 |
Why?
|
| Drug Monitoring | 2 | 2020 | 962 | 0.130 |
Why?
|
| Alkaline Phosphatase | 1 | 2020 | 854 | 0.130 |
Why?
|
| Fatigue | 2 | 2020 | 1549 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2009 | 3111 | 0.130 |
Why?
|
| Hepatic Stellate Cells | 1 | 2016 | 117 | 0.120 |
Why?
|
| Remission Induction | 2 | 2019 | 2411 | 0.120 |
Why?
|
| Hepatic Encephalopathy | 1 | 2016 | 143 | 0.120 |
Why?
|
| Proton Pump Inhibitors | 2 | 2011 | 553 | 0.120 |
Why?
|
| Radiography, Abdominal | 1 | 2018 | 544 | 0.120 |
Why?
|
| Humans | 33 | 2020 | 765968 | 0.120 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 183 | 0.110 |
Why?
|
| Cytosol | 1 | 2017 | 885 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2020 | 8067 | 0.110 |
Why?
|
| NAD | 1 | 2017 | 619 | 0.110 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 6309 | 0.100 |
Why?
|
| Biopsy | 2 | 2018 | 6763 | 0.100 |
Why?
|
| Immune Tolerance | 2 | 2012 | 2324 | 0.100 |
Why?
|
| Waiting Lists | 1 | 2017 | 777 | 0.100 |
Why?
|
| Methotrexate | 1 | 2019 | 1722 | 0.100 |
Why?
|
| Anti-Ulcer Agents | 2 | 2011 | 112 | 0.100 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2012 | 75 | 0.100 |
Why?
|
| Butyrates | 1 | 2012 | 162 | 0.100 |
Why?
|
| Ethanol | 1 | 2018 | 1323 | 0.090 |
Why?
|
| Fatal Outcome | 2 | 2016 | 1831 | 0.090 |
Why?
|
| Mesentery | 1 | 2012 | 199 | 0.090 |
Why?
|
| Intestinal Mucosa | 3 | 2012 | 3046 | 0.090 |
Why?
|
| Biosensing Techniques | 1 | 2017 | 642 | 0.090 |
Why?
|
| Interleukin-23 | 1 | 2012 | 202 | 0.090 |
Why?
|
| Female | 18 | 2020 | 396112 | 0.090 |
Why?
|
| Hepatitis B | 1 | 2016 | 707 | 0.090 |
Why?
|
| Salmonella Infections, Animal | 1 | 2010 | 60 | 0.090 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 1744 | 0.090 |
Why?
|
| Adult | 13 | 2020 | 223044 | 0.090 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2015 | 504 | 0.090 |
Why?
|
| Gram-Negative Bacteria | 1 | 2012 | 275 | 0.090 |
Why?
|
| Male | 17 | 2020 | 363698 | 0.080 |
Why?
|
| Dextran Sulfate | 1 | 2011 | 255 | 0.080 |
Why?
|
| Weight Gain | 1 | 2020 | 2355 | 0.080 |
Why?
|
| Bismuth | 1 | 2009 | 28 | 0.080 |
Why?
|
| Breath Tests | 1 | 2011 | 297 | 0.080 |
Why?
|
| Feces | 2 | 2020 | 1504 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2014 | 910 | 0.080 |
Why?
|
| Mice | 8 | 2020 | 81819 | 0.080 |
Why?
|
| HIV | 1 | 2016 | 1585 | 0.080 |
Why?
|
| Hepacivirus | 1 | 2016 | 1343 | 0.080 |
Why?
|
| Antacids | 1 | 2009 | 94 | 0.080 |
Why?
|
| Clarithromycin | 1 | 2009 | 87 | 0.080 |
Why?
|
| Interleukins | 1 | 2014 | 791 | 0.080 |
Why?
|
| Tetracycline | 1 | 2009 | 216 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2018 | 2132 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 6 | 2017 | 22332 | 0.080 |
Why?
|
| Interleukin-12 | 1 | 2011 | 579 | 0.080 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 305 | 0.080 |
Why?
|
| Amoxicillin | 1 | 2009 | 180 | 0.080 |
Why?
|
| Metronidazole | 1 | 2009 | 236 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 2880 | 0.070 |
Why?
|
| Immunity, Mucosal | 1 | 2011 | 498 | 0.070 |
Why?
|
| Middle Aged | 9 | 2020 | 223009 | 0.070 |
Why?
|
| Adoptive Transfer | 1 | 2009 | 827 | 0.070 |
Why?
|
| Interferon Type I | 1 | 2011 | 567 | 0.070 |
Why?
|
| Echocardiography | 1 | 2020 | 5045 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 5526 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 7425 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2018 | 3141 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2017 | 2892 | 0.070 |
Why?
|
| Animals | 11 | 2020 | 168764 | 0.070 |
Why?
|
| Prevalence | 2 | 2020 | 15842 | 0.060 |
Why?
|
| Amifostine | 1 | 2005 | 39 | 0.060 |
Why?
|
| Radiation-Protective Agents | 1 | 2005 | 87 | 0.060 |
Why?
|
| United States | 6 | 2020 | 72903 | 0.060 |
Why?
|
| Mice, Knockout | 1 | 2020 | 14448 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 14652 | 0.060 |
Why?
|
| Herpes Zoster | 1 | 2007 | 252 | 0.060 |
Why?
|
| Antigens, Bacterial | 1 | 2009 | 1146 | 0.060 |
Why?
|
| Apoptosis | 1 | 2020 | 9514 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 15880 | 0.060 |
Why?
|
| Young Adult | 3 | 2020 | 59889 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2011 | 2927 | 0.050 |
Why?
|
| Microscopy, Confocal | 1 | 2009 | 1966 | 0.050 |
Why?
|
| Hepatitis C | 1 | 2014 | 1597 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2011 | 1069 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 3 | 2011 | 7478 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2020 | 41649 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 10383 | 0.050 |
Why?
|
| Bone Development | 1 | 2005 | 468 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2009 | 1624 | 0.050 |
Why?
|
| Intestines | 1 | 2011 | 1906 | 0.050 |
Why?
|
| Escherichia coli | 2 | 2012 | 4214 | 0.050 |
Why?
|
| Hospitalization | 2 | 2019 | 10808 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 986 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 1995 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2016 | 12976 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2020 | 81514 | 0.040 |
Why?
|
| Disease Progression | 1 | 2017 | 13632 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2011 | 2226 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2009 | 2692 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2009 | 5501 | 0.040 |
Why?
|
| Sigmoidoscopy | 1 | 2019 | 150 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 1899 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2005 | 1181 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2012 | 18973 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 8611 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2020 | 23601 | 0.030 |
Why?
|
| Decerebrate State | 1 | 2016 | 42 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 379 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2009 | 3837 | 0.030 |
Why?
|
| Time Factors | 3 | 2017 | 40065 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2011 | 9347 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2012 | 18293 | 0.030 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2016 | 141 | 0.030 |
Why?
|
| Rats, Inbred Lew | 1 | 2017 | 1167 | 0.030 |
Why?
|
| Aged | 3 | 2020 | 171117 | 0.030 |
Why?
|
| Netherlands | 1 | 2020 | 2277 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 10729 | 0.030 |
Why?
|
| Luminescent Proteins | 1 | 2017 | 839 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2016 | 525 | 0.030 |
Why?
|
| Gallbladder | 1 | 2016 | 308 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2009 | 12768 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 59489 | 0.030 |
Why?
|
| Unconsciousness | 1 | 2016 | 250 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2009 | 10429 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2017 | 1524 | 0.030 |
Why?
|
| Metabolome | 1 | 2020 | 1005 | 0.030 |
Why?
|
| Prisoners | 1 | 2016 | 316 | 0.030 |
Why?
|
| Treatment Outcome | 4 | 2020 | 65188 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2016 | 1336 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 339 | 0.030 |
Why?
|
| Child | 1 | 2020 | 80564 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 2218 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 36532 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 2011 | 214 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2019 | 1587 | 0.020 |
Why?
|
| Interferons | 1 | 2014 | 714 | 0.020 |
Why?
|
| Cecum | 1 | 2010 | 232 | 0.020 |
Why?
|
| Transfection | 1 | 2017 | 5743 | 0.020 |
Why?
|
| Endotoxins | 1 | 2012 | 516 | 0.020 |
Why?
|
| Brain | 1 | 2016 | 27171 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2016 | 896 | 0.020 |
Why?
|
| Prognosis | 2 | 2020 | 29922 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2010 | 824 | 0.020 |
Why?
|
| Salmonella typhimurium | 1 | 2010 | 348 | 0.020 |
Why?
|
| Risk Factors | 2 | 2018 | 74840 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2016 | 2485 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 39193 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2012 | 1441 | 0.020 |
Why?
|
| Metagenome | 1 | 2011 | 464 | 0.020 |
Why?
|
| Probiotics | 1 | 2011 | 387 | 0.020 |
Why?
|
| Proteomics | 1 | 2020 | 3910 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 1959 | 0.020 |
Why?
|
| Sex Factors | 1 | 2020 | 10603 | 0.020 |
Why?
|
| Pentoxifylline | 1 | 2005 | 54 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2020 | 54802 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 4209 | 0.020 |
Why?
|
| Radiography | 1 | 2016 | 6919 | 0.020 |
Why?
|
| Misoprostol | 1 | 2005 | 94 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 2412 | 0.010 |
Why?
|
| Th17 Cells | 1 | 2010 | 786 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2016 | 5993 | 0.010 |
Why?
|
| Age Factors | 1 | 2020 | 18380 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2014 | 8278 | 0.010 |
Why?
|
| Cell Line | 1 | 2016 | 15543 | 0.010 |
Why?
|
| Colon | 1 | 2010 | 1795 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2020 | 22223 | 0.010 |
Why?
|
| Random Allocation | 1 | 2005 | 2395 | 0.010 |
Why?
|
| Bacteria | 1 | 2011 | 2209 | 0.010 |
Why?
|
| Tibia | 1 | 2005 | 1062 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 20124 | 0.010 |
Why?
|
| Comorbidity | 1 | 2014 | 10563 | 0.010 |
Why?
|
| Risk | 1 | 2010 | 9591 | 0.010 |
Why?
|
| Lung | 1 | 2016 | 10033 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 17075 | 0.010 |
Why?
|
| Knee Joint | 1 | 2005 | 1656 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2018 | 24282 | 0.010 |
Why?
|
| Models, Biological | 1 | 2012 | 9443 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2005 | 8102 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 11888 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 88835 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 23707 | 0.010 |
Why?
|
Concepts
(232)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(27)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_